Wilson Sonsini partner Matt Bresnahan is the featured guest on the latest episode of Good Medicine, a podcast hosted by Dr. David Bearss, an accomplished biopharmaceutical executive, entrepreneur, and researcher with over 30 years of experience in the life sciences industry, including as co-founder, president, and CEO of Wilson Sonsini client Halia Therapeutics. In the episode, titled “Protecting Biotech Innovation: Patent Insights with Matt Bresnahan,” Matt discusses what qualifies as patent-eligible and why biotech innovations have to walk a fine line; how the patent clock starts ticking and what it means for drug development timelines; and how the patent system is designed to push innovation toward solving unmet medical needs, benefiting patients and driving down long-term costs, among other topics.

Each episode of Good Medicine dives deep into a wide range of topics, including healthcare economics, global health, cutting-edge scientific advancements, patient journeys, and crucial health/disease issues that affect both individuals and populations.

Click here to watch the full episode.